Company Overview of Genentech, Inc.
Genentech, Inc., a biotechnology company, engages in the research, development, manufacture, and marketing of biotechnology products for treating patients with serious or life-threatening diseases in the United States. It offers molecular entities and medicines in the areas of oncology, immunology, neuroscience, metabolism, and infectious diseases. The company also offers hematology medicines that include antibody-drug conjugates, small molecule antagonists, and small molecule BCL-2 inhibitors. Genentech, Inc. has a strategic alliance with Array biopharma. The company was founded in 1976 and is headquartered in South San Francisco, California. Genentech, Inc. operates as a subsidiary of Roch...
1 DNA Way Mailstop 258A
South San Francisco, CA 94080-4990
Founded in 1976
Key Executives for Genentech, Inc.
Chief Executive Officer, Head of North American Commercial Operations and Director
Co-Founder and Member of Scientific Resource Board
Senior Vice President and General Counsel
Chief Compliance Officer, Head of Legal Affairs for North America, Senior Vice President and Secretary
Vice President of Human Resources and Regional Human Resources Head of North America
Compensation as of Fiscal Year 2015.
Genentech, Inc. Key Developments
Genentech Announces Positive Results from Two Pivotal Studies Evaluating the Investigational Medicine Ocrelizumab
Jun 30 15
Genentech announced positive results from two pivotal studies evaluating the investigational medicine ocrelizumab compared with interferon beta-1a (Rebif®), a standard-of-care therapy, in people with relapsing multiple sclerosis (MS), the most common form of the disease. The studies (called OPERA I and OPERA II) met their primary and major secondary endpoints. Treatment with ocrelizumab significantly reduced the annualized relapse rate (ARR) over a two-year period compared with interferon beta-1a, the primary endpoint in both studies. Ocrelizumab also significantly reduced the progression of clinical disability compared with interferon beta-1a, as measured by the Expanded Disability Status Scale (EDSS). Additionally, treatment with ocrelizumab led to a significant reduction in the number of lesions in the brain (areas of disease activity) compared with interferon beta-1a, as measured by MRI. Overall, the incidence of adverse events associated with ocrelizumab was similar to interferon beta-1a in both studies; the most common adverse events were mild-to-moderate infusion-related reactions. The incidence of serious adverse events associated with ocrelizumab, including serious infections, was also similar to interferon beta-1a.
Almac Discovery Ltd. and Genentech Inc. Sign Research and Licensing Agreement
Jun 16 15
Almac Discovery Ltd. announced that it had signed a research and licensing agreement with Genentech Inc. Almac and Genentech will work together to discover and develop small molecule inhibitors of a ubiquitin specific protease (USP) target. The company will be paid USD 14.5 million (EUR 12.9 million) upfront and stands to receive up to USD 349 million on top of that from milestone payments and escalating tiered royalties tied to commercial sales results. The joint research programme will run for two years, using as its starting point the small molecule inhibitors developed by Almac. Genentech's responsibilities will involve all pre-clinical and clinical development and commercialization of products created by the partners under this collaboration.
Genentech, Inc. Presents at BIO International Convention 2015, Jun-16-2015 10:45 AM
Jun 11 15
Genentech, Inc. Presents at BIO International Convention 2015, Jun-16-2015 10:45 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Mark Rowen, Associate Director, Business Development.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|